StockWatch
·

National Stock Exchange of India Ltd Q2 FY27 Results

NSEQ2 FY27 Results
Filing
Result:Good· Market: Flat#Base effect#Margin expansion

Beat/Miss: Beat · Outlook: Cautiously Optimistic · Guidance: None

MetricValue (₹ Cr)
Revenue4.1K
Total Income4.6K
Expenditure1.2K
PBT3.4K
Net Profit2.6K
OPM75.72%
NPM56.60%
EPS10.41
View full financials

Core transaction revenue grew a healthy 10.6% YoY with adjusted PAT growth of ~13% (the reported +22.8% is a base-effect artifact from prior-year one-off gain/provision), both beating street estimates with modest genuine margin expansion.

NSE · Q2 FY27 · THE VERDICT

Record margins mask the volume debate NSE cannot avoid

NSE posted exceptional profitability (56.6% NPM, 23% PAT growth) but buried a critical headwind: equity derivatives fell 11.7% YoY. The debate is whether this is cyclical weakness or the start of a structural shift.

09 Nov 2026 · 6 min read
Reported Revenue

₹4,067 Cr

+11% YoY

Reported PAT

₹2,578 Cr

+23% YoY

Net Profit Margin

56.6%

Utility-grade profitability

Transaction Charges

₹3,035 Cr

75% of revenue, +9% YoY

NSE delivered a textbook quarter by the headline metrics — revenue and profit both grew, margins are exceptional — but the earnings call revealed a stock exchange grappling with a real debate. Equity derivatives volumes, the engine of transaction revenue, fell 11.7% year-on-year to ₹1.25L Cr in average daily turnover. Cash market activity was up 24% YoY but dropped 13% sequentially. The company is making money hand-over-fist, but on smaller transaction volumes in its core product. That gap between what the P&L shows and what the operating metrics signal is where the quarter lives.

Where the profit came from — and what it rests on

Transaction charges drove ₹3,035 Cr of operating revenue (+9% YoY), making up three-quarters of the top line. This segment is hyper-leveraged to equity market activity. Commodity derivatives — particularly crude oil and electricity futures — surged: commodity options premium turnover jumped roughly 10-fold over nine months (₹880 Cr in January 2026 to ₹8,200 Cr by October 2026). Listing services revenue more than doubled to ₹150 Cr (+70% YoY), driven by 62 listings in the quarter and primary market capital raised up 64% YoY to ₹7.4L Cr. Data services grew 8% YoY to ₹531 Cr, a smaller wedge but one where NSE Data & Analytics posted 61% PAT growth — a signal that pricing power exists outside transaction charges.

Q2 FY27 Revenue, ₹ Cr
01,133.072,266.133,399.23,035Transaction charges150Listing services531Data services351Other
Transaction charges dominate (75% of revenue), but listing and data services are the bright spots.
Management's claims vs. what holds up

Revenue from operations increased 11% YoY to ₹4,067 Cr

Delivered ₹4,066.8 Cr; matches guidance precisely

Supported

PAT increased 23% YoY to ₹2,578 Cr

Delivered ₹2,577.6 Cr; exceptional operating leverage

Supported

Cash market ADT up 24% YoY despite 13% QoQ decline

April-June ₹1.35L Cr → Q2 ₹1.18L Cr (seasonal); YoY ₹1.12L Cr shows 24% growth

Supported

Equity futures ADT declined 11.7% YoY to ₹1.25L Cr due to tax changes and market conditions

Correct figure; management attributed to policy impact and settlement mechanics but stopped short of distinguishing cyclical from structural

Accurate but incomplete diagnosis

What changed on this call

Commodity derivatives have become a real diversifier. The 10-fold surge in commodity options premium in nine months, driven by co-location adoption and expiry date extensions, signals that NSE can grow outside equity volumes. This was not a given six months ago; it's now a material hedge against equity softness. Listing momentum reversed. After a period of slowdown, primary market capital raised jumped 64% YoY; NSE closed 62 listings in Q2 (single-month record of 31 in September). This diversification from trading fees is critical — it's not contingent on equity market volatility. Data services entered monetization mode. Market Lens, NSE's new analytics platform, launched in free beta with ~10,000 datasets to build adoption; management priced a potential paid tier at ₹6,000–₹10,000 per annum per user. NSE Data & Analytics grew PAT 61% YoY, suggesting the infrastructure to support pricing exists. The catch: no timeline on when the transition from free to paid happens.

The bull-bear ledger
  • Exceptional profitability: 56.6% NPM, 19% ROE on utility-scale revenue base

  • Market dominance: 92% equity cash share, regulatory moat defensible

  • Diversification working: listing services +70%, commodities ~10x in 9 months, data PAT +61%

  • Equity derivatives down 11.7% YoY; management signals structural not cyclical headwind

  • Transaction concentration: 75% of revenue from charges; regulatory sensitivity extreme

  • Cash market down 13% QoQ; macro headwinds (CAS, bank guarantees, FII flows) unresolved

  • Data monetization speculative: free-to-paid timing and adoption curve not quantified

  • Strong balance sheet: ₹28,907 Cr net worth, ₹52,613 Cr treasury investments; capital allocation disciplined

Risks, ranked by how much they should concern a holder

Equity derivatives volume decline is structural, not cyclical

High

Equity futures down 11.7% YoY and represent 39% of transaction revenue. Tax policy changes (cited by management) and settlement mechanics are durable, not one-time. If derivatives don't stabilize, transaction charges (75% of revenue) compress materially. The November SEBI reforms are meant to help, but outcome is not guaranteed.

Transaction concentration + regulatory sensitivity

High

Three-quarters of revenue from transaction charges; SEBI controls expiry dates, margin rules, settlement mechanics. Any change to weekly options expiry (42% of total options revenue), EPI margins, or CAS rules can recut earnings overnight. The regulatory moat is also a double-edged sword.

Cash market softness persists (macro headwinds)

Medium

Cash ADT down 13% QoQ despite +24% YoY. Management attributed to CAS system changes and bank guarantee regulations, but geopolitical tensions and FII outflows (also cited) are ongoing. If macro stays soft, listing services and commodities may not offset equity cash weakness.

Data monetization execution

Medium

Market Lens free-to-paid transition timing is vague. Even at ₹6k–₹10k per annum per user, adoption risk is material — competition from Bloomberg, RefinitivI is fierce. NSE has first-mover advantage in Indian market data, but pricing power is unproven at scale.

Market sentiment and FII participation

Medium

NSE volumes are tied to equity market sentiment. FII outflows, interest rate hikes, or geopolitical shocks can compress volumes materially. Domestic institutional bid has been steady (22 consecutive quarters of net buys), but FPI is cyclical.

How the street is positioned

NSE is trading at ₹1,928, near its all-time high of ₹1,953, having rallied 17.55% off its 52-week low of ₹1,640. The stock is above its 20-day simple moving average (₹1,788), signaling upward momentum. However, the RSI of 71.8 flags overbought conditions — a technical warning that the rally may pause for profit-taking. Volume is increasing, which can support momentum, but the combination of near-ATH prices, overbought RSI, and strong momentum suggests that the market has already absorbed the Q2 result and the long-term structural story. At current levels, NSE is priced for near-term execution and the successful rollout of new products (Corporate Bond Futures, data monetization). Any disappointment on equity derivatives stabilization or on the December SEBI reforms could trigger a drawdown — the stock has limited room to run without a fresh catalyst.

What to watch next
  • 1 · December SEBI reforms and cash market rebound

    NSE explicitly flagged SLB and CAS modifications expected in December 2026 as catalysts for expanded cash market activity. If these reforms fail to drive ADT back toward ₹1.3L Cr levels or if FII participation remains muted, the volume narrative shifts from 'temporary softness' to 'structural headwind.' This is the test case for the bull thesis.

  • 2 · Equity derivatives stabilization by Q3

    The -11.7% YoY decline in equity futures ADT is the elephant in the room. Management has not signaled when or how this stabilizes. Q3 earnings will show whether the decline slowed, reversed, or accelerated. This is the binary that determines whether transaction charges grow or contract.

  • 3 · Data monetization roadmap (Q3 or H2 update)

    Market Lens is still in beta with no paid tier launched. NSE needs to articulate the timing and pricing strategy for converting free users to paid. If adoption reaches 50,000+ users during beta, the ₹6k–₹10k per annum per user pricing becomes more credible. Lack of progress here signals data services remain a long-tail growth story, not a near-term earnings inflator.

NSE delivered a strong Q2 by the headline metrics, but the quarter is as much about what didn't grow as what did. Equity derivatives volumes fell 11.7% YoY — a structural headwind management has not resolved. Listing services and commodity derivatives are bright spots, but they are not yet large enough to offset the core transaction charge base. The long-term structural story (market development, data monetization, regulatory moat) remains intact, but the near-term debate is critical: can new products and market reforms offset equity volume decline, or is this the start of a margin compression cycle?

The stock is trading near all-time highs with overbought technicals, suggesting the market is already pricing in a successful answer to that debate. For a holder, the view is a cautious Hold — the company is executing well, but valuation and technicals offer limited margin of safety. For an interested buyer, wait for either (a) December SEBI reforms to prove they expand cash market activity, or (b) a pullback to the 20-day moving average on profit-taking. The number to track from here is equity derivatives ADT — if it stabilizes or rebounds in Q3, the bull thesis holds; if it deteriorates further, the debate shifts to downside risk.

Informational and educational content only. Not investment advice.